OMAHA- The University of Nebraska Medical Center has signed a master clinical trial agreement with COVAXX, a subsidiary of United Biomedical, a recognized leader in antibody diagnostics and vaccine development.
The agreement provides a framework for UNMC to conduct clinical trials, using COVAXX-created therapeutics. With respect to the COVID-19 pandemic, UNMC trials will focus preliminarily on conducting Phase I/II human trials in the United States of COVAXX’s UB-612 vaccine. The COVAXX vaccine is designed to provide both humoral and cellular immune responses. The vaccine clinical trial agreement between UNMC and COVAXX is the second COVID-19 related partnership in 2020 between the two organizations.
In May, UNMC and COVAXX signed a memorandum of understanding that allowed for large-scale, COVID-19 antibody diagnostic testing and processing.